Globus Medical, Inc. (NYSE:GMED) Q3 2024 Earnings Conference Call November 5, 2024 6:00 PM ET
Company Participants
Brian Kearns - SVP, Business Development and IR
Daniel Scavilla - President and CEO
Keith Pfeil - COO and CFO
Conference Call Participants
Matthew Miksic - Barclays
Dino Weinstock - Wells Fargo
Young Li - Jefferies
Shagun Singh - RBC Capital Markets
Phil Dantoin - Piper Sandler
David Saxon - Needham & Company
Steven Lichtman - Oppenheimer
Matthew Blackman - Stifel
Ryan Zimmerman - BTIG
Craig Bijou - BofA
Caitlin Cronin - Canaccord
Richard Newitter - Truist Securities
Operator
Welcome to Globus Medical's Third Quarter 2024 Earnings Call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks. I will now turn the call over to Brian Kearns, Senior Vice President of Development and Investor Relations. Mr. Kearns, please go ahead.
Brian Kearns
Thank you, Victor, and thank you everyone for being with us today. Joining today's call from Globus Medical will be Dan Scavilla, President and CEO; and Keith Pfeil, Chief Operating Officer and Chief Financial Officer. This review is being made available via webcast accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com.
Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements. Our form 10-K for the 2023 fiscal year and our subsequent filings with the Securities and Exchange Commission identifies certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today.
Our SEC filings, including the 10-K are available on our website. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. Our discussion today will also include certain financial measures that are not calculated in accordance with Generally Accepted Accounting Principles or GAAP.
We believe these non-GAAP financial measures provide additional information pertinent to our business performance. These non-GAAP financial measures should not be considered replacements for and should be read together with the most directly comparable GAAP financial measures.
Reconciliations to the most directly comparable GAAP measures are available in the schedules accompanying the press release and on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Dan Scavilla, our President and CEO.